Complying with FCPA and Related Anti-Corruption Measures

is being presented by David F. Axelrod, Managing Member, with Axelrod Laliberte LLP and airs on Wednesday, June 22nd, 2011. For more details, or to register please visit our site at www.fxconferences.com

For the first 20 years of its existence, the Foreign Corrupt Practices Act (FCPA) was rarely used, and EU countries had nothing comparable. More recently, however, the FCPA has been aggressively enforced against individuals, as well as U.S. and foreign companies. Fines have been imposed at unprecedented levels and individuals (including a former U.S. Congressman) jailed. EU governments have also gotten serious about fighting corruption, starting with the 1998 OECD convention against bribery and culminating, so far, with the UK anti-bribery statute.

This audio conference presentation looks at the history, scope and elements of the FCPA, anti-corruption compliance programs, red flags, investigations, and U.S. government expectations for pre-transaction due diligence. It also covers defenses and policy considerations concerning a key exception to liability, facilitating payments. Our speaker also discusses the UK anti-bribery statute and its key differences from the FCPA. Finally, the presentation looks at the relevance of the statute to smaller companies that may have only a limited overseas presence.

FCPA Compliance Strategies for Medical Device & Pharma Companies

The Foreign Corrupt Practices Act (FCPA) has had a major impact on the way companies conduct business abroad. A U.S. anti-corruption law jointly enforced by the Department of Justice and the Securities and Exchange Commission, its main provisions deal with improper payments to foreign officials and questionable accounting practices used to hide them. Violating the FCPA can result in both criminal and civil penalties, and the requirements are complex, applying to both companies in the U.S. and foreign-based companies subject to U.S. securities laws. Past enforcement actions have crossed industry boundaries and included the pharmaceutical industry. Lately, there has been an increase in FCPA enforcement activity in the medical device industry as well.

In this audio conference, our speakers combine their experience with real-world case studies to provide a clear background on the FCPA requirements and enforcement trends, along with practical compliance strategies to keep device and pharma companies from running afoul of the law.

FCPA Compliance Strategies for Medical Device & Pharma Companies is being presented by Bethany Hills & Michelle Merola, with Hodgson Russ LLP and airs Wednesday, April 1, 2009. For more details or to register for this event, please visit our site www.fxconferences.com